Revakinagene taroretcel is an allogeneic encapsulated cell-based gene therapy used to treat idiopathic macular telangiectasia type 2 in adults. Revakinagene taroretcel is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF).
- Mechanism
- Curator reviewed · 4 references
Revakinagene taroretcelis secretes recombinant human ciliary neurotrophic factor (rhCNTF), which is one of several neurotrophic factors endogenously produced by neurons and supporting glial cells. Exogenous CNTF is thought to initially target Müller glia to trigger a cascade of signalling events that may promote photoreceptor survival: CNTF administration was shown to dose-dependently increase retinal thickness in patients with age-related maculopathy and retinitis pigmentosa. However, the mechanism of action for revakinagene taroretcelis is not completely understood.
- Primary indication
- Revakinagene taroretcelis is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).Curator reviewed · 1 structured indication
- First approval
- United States, 2025
- Also known as
- Allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid encoding human ciliary neurotrophic factor (CNTF). An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid · allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor · CILIARY NEUROTROPHIC FACTOR · Ciliary neurotrophic factor - Neurotech · CILIARY NEUROTROPHIC FACTOR (HUMAN)
- Code names
- NT-501 · NTC-201-6A
- Brand names
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with Revakinagene taroretcel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account